source
- GSK to acquire Chimagen’s trispecific T-cell engager program in deal up to $750 millionGSK announced it will acquire a preclinical trispecific T cell engager program from Chinese biotech Chimagen Biosciences in a transaction that could total up to $750 million. The agreement provide…
- FDA approves Telix's Pixclara, first FET-PET imaging drug for glioma in the U.S.The U.S. Food and Drug Administration has granted approval to Telix Pharmaceuticals' Pixclara, a fluorine‑18 labeled amino acid PET tracer designed for imaging gliomas. This marks the first FDA‑cle…